Search results
Earnings call: Pfizer raises 2024 EPS outlook despite revenue decline By Investing.com
Investing.com· 5 days agoDespite a 19% decline in total company revenues to $14.9 billion, primarily due to the reduced...
Pfizer lifts profit view on cost cuts, demand for COVID products
Reuters· 5 days agoSales of Padcev, a treatment for advanced bladder cancer Pfizer gained through its $43 billion deal...
BioNTech says 90% of 2024 revenues will accrue at end of year
Reuters· 14 hours ago, opens new tab was widely used during the pandemic, said on Monday that almost all of its expected...
Supreme Court rejected military chaplains' lawsuit saying their careers were ruined after refusing...
Business Insider· 5 days agoThe Supreme Court denied military chaplains' lawsuit claiming retaliation for refusing the COVID-19 ...
BioNTech says 90% of 2024 revenues will accrue at end of year
WSAU Wausau· 14 hours agoFRANKFURT (Reuters) - Germany's BioNTech, whose COVID-19 vaccine in partnership with Pfizer was...
Pfizer profits drop on lower Covid-19 product sales
Digital Journal· 6 days agoPfizer reported a drop in profits on lower sales of Covid-19 related profits Wednesday as it steers investments to other pharmaceutical areas and...
COVID Vaccine Side Effects: 4 Takeaways From Our Investigation
The New York Times via Yahoo News· 3 days agoThey prevented about 14.4 million deaths worldwide, according to one estimate. In a small percentage...
Analyst Report: BioNTech SE
Morningstar Research via Yahoo Finance· 5 hours agoThe company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies ...
Pfizer Jumps On 'Massive' First-Quarter Upside Thanks To Paxlovid Surprise
Investor's Business Daily· 5 days agoThat was partly due to a one-time $771 million infusion after the U.S. government returned 5.1...
Pfizer Earnings Top Views; Boosts Full-Year Guidance
Morningstar· 6 days agoBy Rob Curran Pfizer posted first-quarter earnings and sales that topped Wall Street targets and boosted its full-year projections as sales of blood thinners and cancer drugs ...